Jitesh Rana, MD - Clinical Trials Daily (Page 3)

Oncology

Clinical Breakthrough at ASH 2025: CLN-049 Demonstrates 50% Response Rate in TP53-Mutated AML via Novel FLT3xCD3 Engagement

Phase 1 data confirms extracellular FLT3 binding efficacy regardless of mutational status, offering a potential breakthrough for refractory subsets. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Perspective Data presented today at

Neurology

TRPM8 Validation: Elismetrep Shows Promise in Phase 2b for Acute Migraine Without Thermoregulation Liability

Kallyope's first-in-class oral antagonist meets co-primary endpoints, offering a distinct non-CGRP mechanism for refractory patients. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Impact Analysis The landscape of acute migraine

Metabolic

Structure's Aleniglipron: Strong Data, Slower Timeline in the Oral GLP-1 Race

Phase 2b results confirm high efficacy and safety, but the pivot to a slower titration protocol pushes Phase 3 to mid-2026, widening the gap with lead competitors. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute

Uncategorized

Oral STAT6 Degradation: A New Frontier in Atopic Dermatitis and Asthma Management?

Phase 1b data from Kymera's KT-621 suggests 'biologic-like' efficacy in an oral pill without the ocular safety liabilities of IL-4Rα inhibitors. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice.

Metabolic

Akero's Efruxifermin: High Efficacy Meets High Maintenance in MASH Landscape

Phase 2b data confirms potent cirrhosis reversal, but safety signals may limit real-world adoption. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Analysis: Efruxifermin in F4 MASH New data from Akero Therapeutics&

Metabolic

Altimmune’s Pemvidutide Achieves 59.1% MASH Resolution: A Potent "Defatting" Engine Faces the Fibrosis Lag Challenge

Phase 2b IMPACT trial data confirms best-in-class liver fat reduction, but a missed 24-week fibrosis endpoint necessitates a strategic pivot for Phase 3 design. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * What

News

Deramiocel Achieves Statistical Significance in Phase 3 HOPE-3 Trial: 54% Slowing of Skeletal Disease Progression and Critical Cardiac Preservation

Capricor Therapeutics’ pivotal data addresses previous regulatory hurdles, positioning the cell therapy as a first-in-class treatment for Duchenne cardiomyopathy.

News

CervoMed’s Neflamapimod Reduces Plasma GFAP by 16% in DLB, Validating 'Bioavailability Hypothesis' for Phase 3

New biomarker data from the RewinD-LB extension confirms that optimized drug delivery reverses neuroinflammation, reviving the asset's commercial potential against a backdrop of unmet need.